Novartis re-launches patient education program

Share this article:
Novartis has embarked "on a mission" to fight hypertension while backing its best-selling product, the blood-pressure-lowering medication Diovan, according to the drugmaker's top financial official.
"We are on a mission in hypertension because we think there is a lot of unmet [patient] need," said Novartis chief operating officer Alex Gorsky speaking at Bear Stearns' annual healthcare conference in New York.
To help achieve its goal of "lowering America's blood pressure," Novartis rebranded and reformatted its Take Action for Healthy BP patient education program as the BP Success Zone. The renamed program, featuring a new compliance component, was launched in July.
BP Success Zone helps patients by providing medication, a free Omron blood pressure monitor with rebate, customized patient education that features lifestyle modification action plans, and a members' Web site with blood pressure tracking tools.
The new compliance component to the program helps promote smoking cessation, a low salt diet, exercise, weight reduction and stress reduction.
Diovan is Novartis' top-selling product, with global sales in the 12 months to June 2005 topping the $1.7 billion dollar mark, according to company figures.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...